NCCN Guidelines for Patients® | Multiple Myeloma - page 82

82
NCCN Guidelines for Patients™: Multiple Myeloma
Version 1.2012
Index
Active myeloma
9, 47 – 54
Adjunctive treatment
30, 31, 47, 50
Anxiety
56
Apheresis
27, 28
Anemia
9, 31, 47, 50
Bisphosphonate
18, 30, 47, 50
Bone marrow
6, 9, 27
Biopsy
16, 27, 42, 44, 44, 46, 48, 51, 52
Blood tests
14
,
42, 44, 44, 46, 48, 51, 52
Caregivers
58, 60
Chemotherapy
24, 25, 47 - 51
Clinical trials
35 – 40
Complementary and alternative medicine
30
Computed tomography
18, 42
Depression
56
Gene changes
16, 43, 64
Graft versus host disease
28
Graft versus tumor effect
26
Magnetic resonance imaging
18, 42
Member institutions
80, 81
M-protein
8, 14, 15
National Comprehensive Cancer Network
1, 78
Panel members
79
Plasma cells
6
Plasmacytoma
31, 47, 50
Positron emission tomography
18, 42
Radiation therapy
23, 28, 44
Treatment response
45
Side effects
28
Sleep
56
Smoldering myeloma
46
Solitary plasmacytoma
7, 23, 44
Stem cells
6
Steroids
24, 25, 47 - 51
Stem cell transplant
26 – 29, 52
Surgery
23, 28, 44
Survivorship
65
Symptoms
9, 10, 30, 31
Targeted therapy
24, 25, 47 - 51
Treatment guide
41 – 54
Treatment planning
62 – 69
1...,72,73,74,75,76,77,78,79,80,81 83,84
Powered by FlippingBook